432 related articles for article (PubMed ID: 15533777)
1. Clinical endocrinology and metabolism. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide.
Meier JJ; Nauck MA
Best Pract Res Clin Endocrinol Metab; 2004 Dec; 18(4):587-606. PubMed ID: 15533777
[TBL] [Abstract][Full Text] [Related]
2. K-cells and glucose-dependent insulinotropic polypeptide in health and disease.
Cho YM; Kieffer TJ
Vitam Horm; 2010; 84():111-50. PubMed ID: 21094898
[TBL] [Abstract][Full Text] [Related]
3. Extrapancreatic effects of GIP and GLP-1.
Vella A; Rizza RA
Horm Metab Res; 2004; 36(11-12):830-6. PubMed ID: 15655715
[TBL] [Abstract][Full Text] [Related]
4. The biology of incretin hormones.
Drucker DJ
Cell Metab; 2006 Mar; 3(3):153-65. PubMed ID: 16517403
[TBL] [Abstract][Full Text] [Related]
5. Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1.
Ranganath LR
J Clin Pathol; 2008 Apr; 61(4):401-9. PubMed ID: 18375745
[TBL] [Abstract][Full Text] [Related]
6. Glucose-dependent insulinotropic polypeptide: from pathophysiology to therapeutic opportunities in obesity-associated disorders.
Paschetta E; Hvalryg M; Musso G
Obes Rev; 2011 Oct; 12(10):813-28. PubMed ID: 21815989
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
Green BD; Gault VA; O'Harte FP; Flatt PR
Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide.
Irwin N; Clarke GC; Green BD; Greer B; Harriott P; Gault VA; O'Harte FP; Flatt PR
Biochem Pharmacol; 2006 Sep; 72(6):719-28. PubMed ID: 16859646
[TBL] [Abstract][Full Text] [Related]
9. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.
Theodorakis MJ; Carlson O; Michopoulos S; Doyle ME; Juhaszova M; Petraki K; Egan JM
Am J Physiol Endocrinol Metab; 2006 Mar; 290(3):E550-9. PubMed ID: 16219666
[TBL] [Abstract][Full Text] [Related]
10. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
Svendsen PF; Nilas L; Madsbad S; Holst JJ
Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579
[TBL] [Abstract][Full Text] [Related]
11. Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility.
Knop FK; Holst JJ; Vilsbøll T
IDrugs; 2008 Jul; 11(7):497-501. PubMed ID: 18600596
[TBL] [Abstract][Full Text] [Related]
12. The incretin hormones GIP and GLP-1 in diabetic rats: effects on insulin secretion and small bowel motility.
Edholm T; Cejvan K; Abdel-Halim SM; Efendic S; Schmidt PT; Hellström PM
Neurogastroenterol Motil; 2009 Mar; 21(3):313-21. PubMed ID: 19126188
[TBL] [Abstract][Full Text] [Related]
13. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
Campbell RK
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
[TBL] [Abstract][Full Text] [Related]
14. [Clinical significance of glucose-dependent insulinotropic polypeptide (GIP)].
Bartos V
Vnitr Lek; 1998 Apr; 44(4):240-4. PubMed ID: 9820111
[TBL] [Abstract][Full Text] [Related]
15. Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP).
McIntosh CH; Widenmaier S; Kim SJ
Vitam Horm; 2009; 80():409-71. PubMed ID: 19251046
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide 1(GLP-1) in biology and pathology.
Meier JJ; Nauck MA
Diabetes Metab Res Rev; 2005; 21(2):91-117. PubMed ID: 15759282
[TBL] [Abstract][Full Text] [Related]
17. New insights into glucose regulation.
Kruger DF; Martin CL; Sadler CE
Diabetes Educ; 2006; 32(2):221-8. PubMed ID: 16554425
[TBL] [Abstract][Full Text] [Related]
18. The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance.
Knop FK; Vilsbøll T; Højberg PV; Larsen S; Madsbad S; Holst JJ; Krarup T
Regul Pept; 2007 Dec; 144(1-3):123-30. PubMed ID: 17692937
[TBL] [Abstract][Full Text] [Related]
19. The contribution of incretin hormones to the pathogenesis of type 2 diabetes.
Meier JJ
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):433-41. PubMed ID: 19748061
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of glucagon secretion.
Young A
Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
